Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain TSRO message board posts where the ticker symbol TSRO has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest TSRO SEC Filings

Filings Format Description Filing Date File/Film Number
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001558370-18-008385 (34 Act)  Size: 7 MB
2018-11-02 001-35587
181157624
8-K  Documents Current report, items 2.02 and 9.01
Acc-no: 0001104659-18-065416 (34 Act)  Size: 236 KB
2018-11-01 001-35587
181153780
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001104659-18-058485 Size: 16 KB
2018-09-25
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0000315066-18-002328 (34 Act)  Size: 9 KB
2018-09-10 005-86904
181061638
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001104659-18-055379 Size: 16 KB
2018-09-05
8-K  Documents Current report, items 7.01 and 9.01
Acc-no: 0001104659-18-055203 (34 Act)  Size: 52 KB
2018-09-05 001-35587
181053970
3  Documents Initial statement of beneficial ownership of securities
Acc-no: 0001104659-18-051944 Size: 15 KB
2018-08-14
SC 13G  Documents Statement of acquisition of beneficial ownership by individuals
Acc-no: 0001193125-18-247324 (34 Act)  Size: 71 KB
2018-08-13 005-86904
181012636
SC 13G  Documents Statement of acquisition of beneficial ownership by individuals
Acc-no: 0001654954-18-008857 (34 Act)  Size: 69 KB
2018-08-13 005-86904
181010303
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-18-021817 Size: 8 KB
2018-08-09
More TSRO SEC Filings


Related news from
Mon, 12 Nov 2018
22:27:55 +0000
CLASS ACTION UPDATE for IGCC, ALGN, AQUA and TSRO: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, Nov. 12, 2018 -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies..
Mon, 12 Nov 2018
14:32:00 +0000
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Tesaro, Inc. (TSRO) and Lead Plaintiff Deadline - January 9, 2019
NEW YORK, NY / ACCESSWIRE / November 12, 2018 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Tesaro, Inc. ("Tesaro" or the "Company") (TSRO) and certain of its officers, on behalf of shareholders who purchased Tesaro securities during the period between November 4, 2016 through November 14, 2016, both dates inclusive (the "Class Period"). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934. On July 7, 2016, Tesaro announced the closing of a previously announced underwritten public offering of common stock, pursuant to which the Company sold 5,347,500 shares at an offering price to the public of $81.00 per share (the "July Offering").
Mon, 12 Nov 2018
13:53:01 +0000
Do Options Traders Know Something About TESARO (TSRO) Stock We Don't?
Investors need to pay close attention to TESARO (TSRO) stock based on the movements in the options market lately.
Sat, 10 Nov 2018
13:05:29 +0000
See what the IHS Markit Score report has to say about TESARO Inc.
Short interest is extremely high for TSRO with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting TSRO. ETFs that hold TSRO had net inflows of $688 million over the last one-month.
Sat, 10 Nov 2018
01:02:22 +0000
Pomerantz Law Firm Announces the Filing of a Class Action against Tesaro, Inc. and Certain Officers – TSRO
Pomerantz LLP announces that a class action lawsuit has been filed against Tesaro, Inc. (“Tesaro” or the “Company”) (TSRO) and certain of its officers. The class action, filed in United States District Court, District of Massachusetts, and indexed under 18-cv-12352, is on behalf of a class consisting of all persons and entities, other than Defendants and their affiliates, who purchased or otherwise, acquired Tesaro securities between November 4, 2016 through November 14, 2016, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
Fri, 09 Nov 2018
22:21:00 +0000
Here's Why AnaptysBio, Inc. Slipped on Friday
The clinical-stage biotech stock slid despite a third-quarter report that didn't contain any surprises.
Fri, 09 Nov 2018
20:41:00 +0000
TESARO Announces Immuno-Oncology Data Presentations at SITC 2018 Annual Meeting
Initial data from AMBER trial of TSR-022 (anti-TIM-3) in combination with TSR-042 (anti-PD-1) demonstrated clinical activity in patients who have progressed following anti-PD-1.
Fri, 09 Nov 2018
18:28:00 +0000
AnaptysBio Inc. Sets Up More Shots on Goal in the Third Quarter
The clinical-stage biotech's third-quarter report contained some important pipeline updates.
Thu, 08 Nov 2018
02:31:19 +0000
Edited Transcript of TSRO earnings conference call or presentation 1-Nov-18 8:15pm GMT
Q3 2018 TESARO Inc Earnings Call
Fri, 02 Nov 2018
18:53:06 +0000
TESARO (TSRO) Q3 Earnings Beat, Revenues Miss, Shares Up
TESARO (TSRO) beats estimates for earnings in the third quarter but misses the same on revenues. Zejula sales maintain momentum.
Fri, 02 Nov 2018
12:01:29 +0000
The Daily Biotech Pulse: Illumina Snaps Up Pacific Bioscience, Thumbs Down For Alkermes Depressive Disorder Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 1) Gritstone Oncology Inc (NASDAQ: GRTS ) Repligen Corporation ...
Thu, 01 Nov 2018
22:20:10 +0000
Tesaro (TSRO) Reports Q3 Loss, Lags Revenue Estimates
Tesaro (TSRO) delivered earnings and revenue surprises of 4.96% and -7.36%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Thu, 01 Nov 2018
21:14:38 +0000
Tesaro: 3Q Earnings Snapshot
The Waltham, Massachusetts-based company said it had a loss of $2.49 per share. The results topped Wall Street expectations. The average estimate of 11 analysts surveyed by Zacks Investment Research was ...
Thu, 01 Nov 2018
20:05:00 +0000
TESARO Announces Third-Quarter 2018 Operating Results
ZEJULA® Q3 net sales totaled $63 million compared to $39 million for Q3 2017Top-line results for PRIMA trial of ZEJULA monotherapy for first-line ovarian cancer patients.
Tue, 30 Oct 2018
12:05:00 +0000
The Foundation for Women’s Cancer and TESARO Partner on the Race to End Women’s Cancer for 3rd Year
The Foundation for Women’s Cancer (FWC), the official foundation of the Society of Gynecologic Oncology (SGO), and TESARO, Inc. (TSRO), an oncology-focused biopharmaceutical company, today announced the third year of their partnership supporting the annual National Race to End Women’s Cancer. The weekend-long event is the FWC’s pinnacle awareness and fundraising event, celebrating survivors, honoring loved ones, creating awareness and supporting women with gynecologic cancers.
Mon, 29 Oct 2018
12:00:00 +0000
TESARO Announces Achievement of ZEJULA Prostate Cancer Development Milestones by Janssen
TESARO, Inc. (TSRO), an oncology-focused biopharmaceutical company, today announced the achievement of development milestones that trigger an $18 million payment from Janssen Biotech Inc. (Janssen). The milestones are related to Janssen’s ongoing GALAHAD trial, which is assessing niraparib monotherapy for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) and DNA-repair anomalies. In addition, data from the Phase 1b BEDIVERE trial were recently presented at the European Society of Clinical Oncology (ESMO) and demonstrated the safety and tolerability of combining niraparib with abiraterone acetate + prednisone (AA-P) in men with mCRPC.
Wed, 24 Oct 2018
22:49:33 +0000
Here's Why Tesaro Inc. Dropped 13.8% Today
Investors continue to digest data from the biotech's competitors.
Wed, 24 Oct 2018
12:35:00 +0000
Factors of Influence in 2018, Key Indicators and Opportunity within YRC Worldwide, NRG Energy, TESARO, The Trade Desk, Foot Locker, and Hertz Global — New Research Emphasizes Economic Growth
NEW YORK, Oct. 24, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Wed, 24 Oct 2018
12:00:00 +0000
TESARO and Actress Cobie Smulders Launch Not on My Watch, a National Movement to Empower the Ovarian Cancer Community
TESARO, Inc. (TSRO), an oncology-focused biopharmaceutical company, announced today the launch of Not on My Watch, a movement to empower the ovarian cancer community, especially women with recurrent ovarian cancer, to take informed and proactive steps against the threat of another disease recurrence. Internationally acclaimed actress Cobie Smulders (the Avengers films, How I Met Your Mother), an ovarian cancer survivor, has directed a public service announcement (PSA) featuring women living with ovarian cancer, who highlight their own experiences and articulate the need for education when faced with a recurrence of the disease. “Like many women who have lived through an ovarian cancer diagnosis, I understand the constant fear that comes in between doctors’ visits around the prospect of the cancer coming back,” Smulders said.
Mon, 22 Oct 2018
20:26:23 +0000
These Companies Are Dragging Biotech Stocks Into A Pit On Cancer Tests
Mirati Therapeutics and Clovis Oncology dragged biotech companies into a pitfall Monday after studies of their cancer treatments disappointed during a meeting in Europe.



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "ValueForum is the gold standard, valuable because of the exceptional people who post here, and because the best of them are candid, detailed and informed. There is little tolerance for the b.s. found on public boards, and management and members are vigilant and aggressive about TOS violations. VF is the gold standard." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards